Latest news

Director/PDMR Shareholding

29 December 2022

Results of AGM

16 December 2022

AGM Statement

16 December 2022

Notice of AGM, Annual Report and Accounts

24 November 2022

Find out more

Featured

TYK2/JAK1 inhibitor SDC-1801, targeting autoimmune diseases, is being prepared for first clinical studies

Find out more large-arrow.png

Pipeline

Sareum's innovative pipeline is focused on the TYK/JAK cell signalling family.

Find out more large-arrow.png

External Presentationssmall-arrow.png

IMC AGM, Dec 2022
IMC SDC-1801 CTA submission, Aug 2022
BioTrinity, April 2022

IMC Half Year Results, Feb 2022